Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Executive Summary
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.
You may also be interested in...
Edwards Keeps TAVR Going During COVID-19 Surge
Fourth-quarter sales of Edwards Sapien transcatheter aortic valve systems grew 2% year-over-year overall, despite the intense challenges created by COVID-19.
Minute Insight: Sema4 To Acquire Genomics Company GeneDx For $623M To Strengthen Clinical Data Platform
Genetic testing company Sema4 announced plans to buy GeneDx to strengthen Sema4’s health intelligence and genomic screening offers. The combined company is expected to generate $350m in pro forma 2022 revenue.
JPM 2022: Boston Scientific, Inspire, Nuvasive, Vericel
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the third day of the meeting.